双氢克尿塞基因对双相 I 型障碍患者抗躁狂药物的影响。
Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder.
机构信息
Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
出版信息
Psychiatry Investig. 2008 Jun;5(2):102-5. doi: 10.4306/pi.2008.5.2.102. Epub 2008 Jun 30.
OBJECTIVE
We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.
METHODS
A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).
RESULTS
There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.
CONCLUSION
Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.
目的
我们之前报道了双调蛋白基因（DTNBP1）变异与双相 I 型障碍（BID）之间的关联。本文扩展了之前的发现，表明 DTNBP1 变异可能在急性心境稳定剂治疗反应中发挥作用。
方法
共有 45 名 BID 患者接受抗躁狂药物（锂盐、丙戊酸盐或卡马西平）治疗，平均 36.52（+/-19.87）天。治疗后，采用临床总体印象量表（CGI）和 Young 躁狂量表（YMRS）对患者进行评估，并对 DTNBP1 变异（rs3213207 A/G、rs1011313 C/T、rs2005976 G/A、rs760761 C/T 和 rs2619522 A/C）进行基因分型。
结果
即使考虑了可能的分层因素，所研究的变异与心境稳定剂治疗反应之间也没有关联。
结论
尽管我们研究中的受试者数量较少是一个重要的局限性，但 DTNBP1 似乎不参与急性抗躁狂疗效。
Zotero 插件